Entries by KellySouthern

Mission Therapeutics commences landmark trial of MTX325, a potential disease-modifying treatment for Parkinson’s Disease

Builds on preclinical proof-of-concept that MTX325 protects dopamine-producing brain cells by enhancing mitophagy – the process cells use to remove dysfunctional mitochondria Cambridge, UK – 21 March 2024 – Mission Therapeutics (“Mission” or the “Company”), a clinical-stage biotech developing first-in-class therapeutics targeting mitophagy, today announces the start of a Phase I first-in-human clinical trial of […]

Mission Therapeutics raises £25.2 million to progress clinical candidates in the area of mitophagy

Developing novel therapeutics which enhance the removal of dysfunctional mitochondria, promoting cell health and function MTX325 is a potentially disease-modifying treatment for Parkinson’s Disease with clinical trial due to start imminently Backed by blue chip international investors Cambridge, UK – March 14, 2024 – Mission Therapeutics (“Mission” or the “Company”), a clinical-stage biotech developing first-in-class […]

Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury

Mission gains clearance from US FDA for Phase II trial of MTX652 after it receives official approval of its Investigational New Drug (IND) application Phase II trial expected to begin Q1 2024 in up to 160 patients with acute kidney injury (AKI) following cardiac surgery Cambridge, UK – December 14, 2023 – Mission Therapeutics (“Mission” […]

Mission Therapeutics granted MHRA Clinical Trial Authorisation (CTA) for MTX325 for the treatment of Parkinson’s Disease

Company on-track to dose first participant in multi-part, adaptive Phase 1, first-in-human study in healthy volunteers and Parkinson’s Disease (PD) patients in the first quarter of 2024 CTA comes as Nature Reviews Drug Discovery hails Mission’s mitophagy approach as “an appealing disease-modifying therapeutic strategy” for PD Cambridge, UK – 5 December 2023 – Mission Therapeutics […]

Mission Therapeutics announces publication in Nature Communications outlining potential of experimental drug MTX325 as a disease-modifying therapy for Parkinson’s Disease

International research collaboration between Harvard Medical School, Cambridge University and Mission Therapeutics CAMBRIDGE, UK, 13 November, 2023 – Mission Therapeutics (“Mission”), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces the publication of a peer-reviewed article titled ‘Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson’s Disease (PD) mouse model’ in […]

Mission Therapeutics to Present Abstract at American Society of Nephrology (ASN) Kidney Week 2023

CAMBRIDGE, UK, 2 November 2023 – Mission Therapeutics (“Mission”), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that it will present an oral abstract on its experimental drug candidate MTX652 at the American Society of Nephrology’s Kidney Week in Philadelphia, from 2-5 November 2023. Mission Therapeutics is a world leader in discovering […]

Mission Therapeutics to Present at Michael J. Fox Foundation’s 15th Annual Parkinson’s Disease Therapeutics Conference

CAMBRIDGE, UK, 10 October 2023 – Mission Therapeutics (“Mission”), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that its Chief Scientific Officer, Dr Paul Thompson, will give an oral presentation on its experimental drug candidate MTX325 at the 15th Annual Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference on October 19, 2023, […]

Mission Therapeutics founder to receive Knighthood in Birthday Honours List

Professor Steve Jackson earns KBE for services to innovation and research CAMBRIDGE, UK – 17 June 2023 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), sends its congratulations to the company’s founder, Professor Steve Jackson, who has been made a Knight Bachelor as […]

Mission Therapeutics to Present at the Targeted Protein Degradation Europe Conference 2023

Presentation at 9am Thursday, March 30th 2023 CAMBRIDGE, UK– 6 March 2023 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), announces that Dr Nick Edmunds, Chief Technology Officer at Mission, will be presenting at the Targeted Protein Degradation Europe conference 2023. Mission Therapeutics’ presentation […]

Mission Therapeutics Successfully Completes First Clinical Assessment for Lead DUB Program, MTX652

Safety, tolerability and pharmacokinetic endpoints successfully met Follow-on clinical trials to be initiated in 2023 CAMBRIDGE, UK – 5 January 2023 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), today announced the successful completion  of its first Phase I clinical assessment for lead […]